Search results for " B-Cell"

showing 10 items of 207 documents

Host-related factors and cancer: Malnutrition and non-Hodgkin lymphoma

2022

Assessment of host-related factors is a crucial aspect in the comprehensive management of cancer patients. A distinct nutritional disturbance linked to cancer has been recognized to be associated with negative outcomes. However, compared to solid tumors, only a limited number of studies have looked specifically at nutritional issues in the field of lymphoma. The aim of this review is to integrate the current knowledge on interactions between malnutrition and lymphoma and address most relevant and pertinent questions. We first provide a literature review on the mutual biological relationship between malnutrition and lymphoma. Next, we explore the overlap between malnutrition, sarcopenia, cac…

Cancer ResearchSarcopeniaCachexiaFrailtyLymphoma Non-Hodgkinnon-Hodgkin lymphomaMalnutritionHematologyGeneral MedicineDiffuse large B-cell lymphomaOncologyNutritional statusNeoplasmsHumansCancer metabolic syndrome
researchProduct

Whole‐body magnetic resonance imaging (WB‐MRI) in lymphoma: State of the art

2019

The improvements in magnetic resonance imaging (MRI) technology and the concern related to the increased cancer risk in patients with lymphoma, also due to radiation exposure associated with imaging examinations, have led to the introduction of whole-body MRI (WB-MRI) as a radiation-free alternative to standard imaging procedures. WB-MRI seems a less histology-dependent functional imaging test than 18 F-fluorodeoxyglucose-positron emission tomography/CT (18 F-FDG-PET/CT). In patients with FDG-avid lymphomas, such as diffuse large B-cell lymphoma (DLBCL) and Hodgkin lymphoma (HL), 18 F-FDG-PET/CT remains the imaging reference standard for staging, with WB-MRI potentially being a complementar…

Cancer Researchmedicine.medical_specialtyLymphomaWhole body imagingFollicular lymphoma03 medical and health sciences0302 clinical medicineimmune system diseaseshemic and lymphatic diseasesmedicineAnimalsHumansT-cell lymphomaWhole Body ImagingB-cell lymphomaAnaplastic large-cell lymphomaNeoplasm Stagingbusiness.industryHematologyGeneral Medicinemedicine.diseaseMagnetic Resonance ImagingPeripheral T-cell lymphomaOncology030220 oncology & carcinogenesisMantle cell lymphomaRadiologybusinessDiffuse large B-cell lymphoma030215 immunologyHematological Oncology
researchProduct

Splenic marginal zone lymphoma proposals for a revision of diagnostic, staging and therapeutic criteria

2007

Since the initial description of splenic marginal zone lymphoma (SMZL) in 1992, an increasing number of publications have dealt with multiple aspects of SMZL diagnosis, molecular pathogenesis and treatment. This process has identified multiple inconsistencies in the diagnostic criteria and lack of clear guidelines for the staging and treatment. The authors of this review have held several meetings and exchanged series of cases with the objective of agreeing on the main diagnostic, staging and therapeutic guidelines for patients with this condition. Specific working groups were created for diagnostic criteria, immunophenotype, staging and treatment. As results of this work, guidelines are pr…

Cancer Researchmedicine.medical_specialtyMEDLINElymphomaComorbiditySettore MED/08 - Anatomia PatologicaAntiviral AgentsImmunophenotypingDiagnosis DifferentialAntibodies Monoclonal Murine-DerivedBone MarrowAntineoplastic Combined Chemotherapy ProtocolsBiomarkers TumormedicineHumansCombined Modality TherapySplenic marginal zone lymphomaIntensive care medicineSplenic marginal zone lymphomaNeoplasm StagingChromosome Aberrationsbusiness.industrySplenic NeoplasmsAntibodies MonoclonalDisease ManagementLymphoma B-Cell Marginal ZoneHematologyHepatitis C ChronicPrognosismedicine.diseaseCombined Modality TherapyComorbidityLymphomaSurgeryClinical trialOncologyPractice Guidelines as TopicSplenectomyRituximabDifferential diagnosisRituximabbusinessguidelineSpleenmedicine.drugLeukemia
researchProduct

IgG1 B cell receptor signaling is inhibited by CD22 and promotes the development of B cells whose survival is less dependent on Ig alpha/beta.

2007

We describe a mouse strain in which B cell development relies either on the expression of membrane-bound immunoglobulin (Ig) gamma1 or mu heavy chains. Progenitor cells expressing gamma1 chains from the beginning generate a peripheral B cell compartment of normal size with all subsets, but a partial block is seen at the pro- to pre-B cell transition. Accordingly, gamma1-driven B cell development is disfavored in competition with developing B cells expressing a wild-type (WT) IgH locus. However, the mutant B cells display a long half-life and accumulate in the mature B cell compartment, and even though partial truncation of the Ig alpha cytoplasmic tail compromises their development, it does…

Cell SurvivalCellular differentiationSialic Acid Binding Ig-like Lectin 2ImmunologyNaive B cellB-cell receptorImmunoglobulinsReceptors Antigen B-CellBiologyArticle03 medical and health sciencesMice0302 clinical medicinemedicineImmunology and AllergyAnimalsProgenitor cellMemory B cellB cell030304 developmental biologyCell ProliferationMice Knockout0303 health sciencesB-LymphocytesCell growthCD22Toll-Like ReceptorsCell DifferentiationArticlesMolecular biologyCell biologyMice Inbred C57BLmedicine.anatomical_structureImmunoglobulin GMutationCalciumDimerizationCD79 AntigensSpleen030215 immunologyProtein BindingSignal TransductionThe Journal of experimental medicine
researchProduct

U937 variant cells as a model of apoptosis without cell disintegration

2012

AbstractThe variant cell line U937V was originally identified by a higher sensitivity to the cytocidal action of tumor necrosis factor alpha (TNFα) than that of its reference cell line, U937. We noticed that a typical morphological feature of dying U937V cells was the lack of cellular disintegration, which contrasts to the formation of apoptotic bodies seen with dying U937 cells. We found that both TNFα, which induces the extrinsic apoptotic pathway, and etoposide (VP-16), which induces the intrinsic apoptotic pathway, stimulated U937V cell death without cell disintegration. In spite of the distinct morphological differences between the U937 and U937V cells, the basic molecular events of ap…

Cell typeProgrammed cell deathBlotting WesternCellApoptosisU937 cellsDNA FragmentationBiologyModels BiologicalBiochemistrymedicineHumansCell ShapeMolecular BiologyU937 cellCytochrome cCytochromes chemic and immune systemsCell BiologyApoptotic bodyCaspase 9MitochondriaCell biologyEnzyme Activationmedicine.anatomical_structureApoptosisCell culturebiology.proteinApoptotic bodiesLymphoma Large B-Cell DiffuseCell disintegrationSignal TransductionResearch ArticleCellular and Molecular Biology Letters
researchProduct

Mast cells control the expansion and differentiation of IL-10-competent B cells

2014

Abstract The discovery of B cell subsets with regulatory properties, dependent on IL-10 production, has expanded our view on the mechanisms that control inflammation. Regulatory B cells acquire the ability to produce IL-10 in a stepwise process: first, they become IL-10 competent, a poised state in which B cells are sensitive to trigger signals but do not actually express the Il-10 gene; then, when exposed to appropriate stimuli, they start producing IL-10. Even if the existence of IL-10–competent B cells is now well established, it is not yet known how different immune cell types cross talk with B cells and affect IL-10–competent B cell differentiation and expansion. Mast cells (MCs) contr…

Cell typeRegulatory B cellsCellular differentiationImmunologyCD40 LigandB-Lymphocyte SubsetsRegulatory B cellsB-cellBiologyExosomesLymphocyte ActivationImmunophenotypingMast cellMiceImmunophenotypingImmune systemmedicineImmunology and AllergyAnimalsMast CellsB cell differentiationCD40 AntigensB cellmast cell; IL-10; B-cellMice KnockoutCD40Cell DifferentiationCell biologyInterleukin-10Gastrointestinal TractInterleukin 10medicine.anatomical_structurePhenotypeMast cell; Regulatory B cells; IL-10; B cell differentiationImmunologyIL-10biology.proteinFemaleJournal of immunology (Baltimore, Md.
researchProduct

Monocytes/macrophages but not T lymphocytes are the major targets of the CCL3/CCL4 chemokines produced by CD38(+)CD49d(+) chronic lymphocytic leukaem…

2010

ChemokineChronic lymphocytic leukemiaT-LymphocytesCCL3CD38Settore MED/08 - Anatomia PatologicaCD49dMonocytesMacrophages; Tumor Cells Cultured; Leukemia Lymphocytic Chronic B-Cell; Humans; Monocytes; Chemokine CCL4; Chemokine CCL3; T-LymphocytesTumor Cells CulturedMedicineMacrophageHumansChronicChemokine CCL4Chemokine CCL3CulturedLeukemiabiologybusiness.industryMonocyteMacrophagesB-CellHematologyT lymphocytemedicine.diseaseLeukemia Lymphocytic Chronic B-CellLymphocyticTumor Cellsmedicine.anatomical_structureImmunologybiology.proteinbusinessSettore MED/15 - Malattie del SangueCCL3/CCL4 CD38CD49d chronic lymphocitic leukemia
researchProduct

Genome-wide association study of follicular lymphoma identifies a risk locus at 6p21.32

2010

To identify susceptibility loci for non-Hodgkin lymphoma subtypes, we conducted a three-stage genome-wide association study. We identified two variants associated with follicular lymphoma at 6p21.32 (rs10484561, combined P = 1.12 × 10-29 and rs7755224, combined P = 2.00 × 10-19; r2 = 1.0), supporting the idea that major histocompatibility complex genetic variation influences follicular lymphoma susceptibility. We also found confirmatory evidence of a previously reported association between chronic lymphocytic leukemia/small lymphocytic lymphoma and rs735665 (combined P = 4.24 × 10-9). © 2010 Nature America, Inc. All rights reserved.

Chronic lymphocytic leukemiaFollicular lymphomaLocus (genetics)Genome-wide association studyHuman leukocyte antigenBiologyArticleMajor Histocompatibility Complex03 medical and health sciences0302 clinical medicinefollicular lymphomaRisk Factorshemic and lymphatic diseasesGeneticsmedicineHumansLymphoma Follicular030304 developmental biology0303 health sciencesLymphoma Non-HodgkinGenetic Variation16. Peace & justicemedicine.diseaseLeukemia Lymphocytic Chronic B-Cell3. Good healthLymphomaNon-Hodgkin's lymphomaLeukemia030220 oncology & carcinogenesisImmunologyDisease SusceptibilityGenome-Wide Association Study
researchProduct

A variant of the LRP4 gene affects the risk of chronic lymphocytic leukaemia transformation to Richter syndrome

2010

Richter syndrome (RS) represents the transformation of chronic lymphocytic leukaemia (CLL) to aggressive lymphoma. Risk factors of CLL transformation to RS are only partly known. We explored the role of the host genetic background as a risk factor for RS occurrence. Forty-five single nucleotide polimorphisms (SNPs) known to be relevant for CLL prognosis were genotyped in a consecutive cohort of 331 CLL, of which 21 had transformed to RS. After correcting for multiple testing and adjusting for previously reported RS risk factors, the LRP4 rs2306029 TT variant genotype was the sole SNP independently associated with a higher risk of RS transformation (Hazard Ratio: 4·17; P = 0·001; q = 0·047).…

Chronic lymphocytic leukemiaSingle-nucleotide polymorphismAggressive lymphomaHematologyBiologymedicine.diseasehemic and lymphatic diseasesImmunologyGenotypemedicineSNPRisk factorGenotypingDiffuse large B-cell lymphomaBritish Journal of Haematology
researchProduct

Interim 18f-PDGPET for Aggressive Non-Hodgking's Lymphoma: A Systematic Review and Meta-Analysis

2011

Abstract Abstract 5183 Background: The advantage of using interim 18F-fluorodeoxyglucose (FDG) positron-emission tomography (PET) scan in the clinical work-up of patients with non-Hodgkin's lymphoma (NLH) is unclear. Data from meta-analyses are inconclusive, mainly because of the low number of patients evaluated and heterogeneity among studies. New clinical investigations, focused on this topic, have been recently published. We conducted an updated systematic review on the role of 18PDG-PET for the interim evaluation in patients with aggressive lymphomas. Materials and Methods: Medline, Embase, Scopus and Databases were searched for relevant studies through March 2011. We included studies t…

Contingency tablemedicine.medical_specialtybusiness.industryImmunologyMEDLINECell BiologyHematologymedicine.diseaseBiochemistryChemotherapy regimenTreatment failureLymphomaMeta-analysisInternal medicineInterimMedicineNuclear medicinebusinessDiffuse large B-cell lymphomaBlood
researchProduct